Neurologic clinical trial - Mitsubishi Acute SCI Phase 2 - MT-3921-A01

Status:

Open and enrolling

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury

Drug

MT-3921

Phase

Phase 2

Condition

Amyotrophic Lateral Sclerosis (ALS) Acute Spinal Cord Injury

Keywords

ALS | Mitsubishi